KR0168721B1 - Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent - Google Patents
Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent Download PDFInfo
- Publication number
- KR0168721B1 KR0168721B1 KR1019950036567A KR19950036567A KR0168721B1 KR 0168721 B1 KR0168721 B1 KR 0168721B1 KR 1019950036567 A KR1019950036567 A KR 1019950036567A KR 19950036567 A KR19950036567 A KR 19950036567A KR 0168721 B1 KR0168721 B1 KR 0168721B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- extracts
- free radical
- antioxidant
- eye
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 32
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 title claims description 5
- 210000000582 semen Anatomy 0.000 title abstract description 5
- 239000003795 chemical substances by application Substances 0.000 title description 3
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 229940123457 Free radical scavenger Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002516 radical scavenger Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000007760 free radical scavenging Effects 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 3
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 230000002790 anti-mutagenic effect Effects 0.000 abstract description 8
- 210000001508 eye Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 5
- 208000030533 eye disease Diseases 0.000 abstract description 3
- 244000277285 Cassia obtusifolia Species 0.000 abstract description 2
- 235000006719 Cassia obtusifolia Nutrition 0.000 abstract description 2
- 244000201986 Cassia tora Species 0.000 abstract description 2
- 235000014552 Cassia tora Nutrition 0.000 abstract description 2
- 238000009835 boiling Methods 0.000 abstract description 2
- 239000002934 diuretic Substances 0.000 abstract description 2
- 230000001882 diuretic effect Effects 0.000 abstract description 2
- 239000008141 laxative Substances 0.000 abstract description 2
- 230000002475 laxative effect Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 229940124595 oriental medicine Drugs 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 8
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- ZMDXTRSTKHTSCE-UHFFFAOYSA-N Chryso-obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2OC ZMDXTRSTKHTSCE-UHFFFAOYSA-N 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- NYRXUBDGDSRBGB-UHFFFAOYSA-N Obtusifolin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(C)C(O)=C2OC NYRXUBDGDSRBGB-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RVRLLYKHCMHGKV-UHFFFAOYSA-N norrubrofusarin Chemical compound C1=C(O)C=C2C=C(OC(C)=CC3=O)C3=C(O)C2=C1O RVRLLYKHCMHGKV-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 241001325860 Lacanobia oleracea Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZCHGCYXNSBHAEG-UHFFFAOYSA-N Obtusifolin Natural products COc1ccc2C=C(C(=O)Oc2c1C=CC(=C)C)C(C)(C)C=C ZCHGCYXNSBHAEG-UHFFFAOYSA-N 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001278475 Syagrus oleracea Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930183235 fusarin Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- FPNKCZKRICBAKG-UHFFFAOYSA-N rubrofusarin Chemical compound O1C(C)=CC(=O)C=2C1=CC1=CC(OC)=CC(O)=C1C=2O FPNKCZKRICBAKG-UHFFFAOYSA-N 0.000 description 1
- KLKFLNXANXGSIT-UHFFFAOYSA-N rubrofusarin Natural products O1C(C)=CC(=O)C2=C1C=C1C=C(O)C=C(OC)C1=C2O KLKFLNXANXGSIT-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
결명자(Cassiae semen)은 초결명자(Cassia obtusifolia L.), 또는 결명(Cassia tora L.)의 종자로서 한방에서 건위, 정장, 이뇨 및 완화제로 쓰이고 동의보감에서는 청간명목(淸肝明目)이라 하여 결명자를 끓인 물로 달여마시면 간에 좋고 나아가 눈을 밝게 한다고 알려져왔다.Cassiae semen (Cassiae semen) is a seed of the superdestructor (Cassia obtusifolia L.), or Cassia tora L. is used as a sanitary, formal, diuretic, and laxative in oriental medicine, and in the sense of consent, it is called as a blue-eyed name (淸 肝 明目). When boiled with boiled water, the liver is known to brighten the eyes.
본 발명은 결명자를 단지 물로 끓여 추출하여 음용했을 때에는 활성성분인 노르-루브로푸사린이 전혀 들어있지 않음을 발견하고, 결명자의 주요성분인 노르-루브로푸사린의 함량이 높은 추출물을 얻기 위하여 결명자분말을 30~100%의 에탄올 수용액으로 추출하여 고농도의 노르-루브로푸사린을 함유하는 결명자 추출물을 제조하는 방법을 제공하는 것이다.The present invention finds that the active ingredient of no-lubrofusarin is not contained at all when the boiled extract is extracted by only boiling with water, and to obtain an extract with a high content of noro-brobrofusarin, which is the main ingredient of the defector. It is to provide a method for producing a deflector extract containing a high concentration of nor- lubrofusarin by extracting the deficiency powder with an aqueous 30% to 100% ethanol solution.
또한, 본 발명은 옛부터 눈에 좋다고 알려져있는 결명자에 대하여 우수한 활성을 갖고 있는 추출물을 제조하고, 이들 추출물과 추출물 중 함유된 활성성분의 항산화활성, 프리라디칼소거작용 및 항돌연변이효과를 확인하여 눈의 노화방지 및 안질환 예방에 관한 용도를 제공하는 것이다.In addition, the present invention is to prepare extracts having excellent activity against the deficiency known to be good for the eye since ancient times, and to check the antioxidant activity, free radical scavenging effect and antimutagenic effect of these extracts and the active ingredient contained in the eye It is to provide a use for the prevention of aging and eye diseases.
Description
본 발명은 결명자로부터 유효성분을 다량 함유하는 추출물의 제조방법 및 이들의 용도에 관한 것으로 특히, 이들 추출물과 추출물 중 함유된 활성성분의 항산화활성, 프리라디칼 소거작용 및 항돌연변이제로서의 용도를 규명한 것이다.The present invention relates to a method for the preparation of extracts containing a large amount of active ingredients from the cultivars and to their use, in particular, to the antioxidant activity, free radical scavenging activity and antimutagenicity of these extracts and active ingredients contained in the extract will be.
결명자(Cassiae semen)는 초결명자(Cassia obtusifolia L.), 또는 결명자(Cassie tora L.)의 종자로서 한방에서 건위, 정장, 이뇨 및 완화제로 쓰이고 동의보감에서는 청간명목(淸肝明目)이라하여 결명자를 달여마시면 간에 좋고 나아가 눈을 밝게 한다고 알려져왔다. 따라서, 최근까지 많은 사람들이 결명자를 끓는 물로 달여서 차로서 마시고 있다.Cassiae semen (Cassiae semen) is the seed of the superdestructor (Cassia obtusifolia L.) or Cassia tora L. is used as a sanitary, formal, diuretic, and laxative in oriental medicine, and in the sense of consent, it is called the bluish name. It is known that if you drink it, it will be good for your liver and brighten your eyes. Therefore, until recently, many people have decoctioned the boiled water with boiling water and drink it as tea.
그동안 결명자에서는 크리소파놀(chrysophanol), 에모딘(emodin), 피시온(physcion) 등의 안트라퀴논과 오브투시폴린(obtusifolin), 오브투신(obtusin), 크리소오부투신(chryso-obtusin), 노르-루브로푸사(nor-rubrofusarin) 및 루브로푸사린(rubrofusarin) 등의 안트라퀴논 배당체가 분리동정된 바 있다. 그러나 현재까지 결명자 중의 어떠한 성분이 활성이 있는지 확실히 규명되어 있지 않다.In the meantime, anthraquinones such as chrysophanol, emodin, and physcion, obtusifolin, obtusin, chryso-obtusin, nord Anthraquinone glycosides, such as nor-rubrofusarin and rubrofusarin, have been isolated and identified. However, to date, it is not clear what component of the defect is active.
또한, 본 발명자는 결명자를 단지 물로 끓여 추출하여 음용했을 때에는 활성성분인 노르-루브로푸사린 등이 전혀 들어있지 않음을 발견하였다.In addition, the present inventors found that when the extract was boiled with water only and extracted and drinked, no active ingredient nor-robrofusarin was contained.
따라서, 본 발명의 목적은 결명자의 주요성분인 노르-루브로푸사린의 함량이 높은 추출물을 제조하는 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for producing an extract having a high content of nolu-brobrofusarin, which is a main component of the deficiency.
본 발명의 또 다른 목적은 상기한 방법에 의하여 추출물 및 추출물 중 함유된 활성성분의 용도를 규명하여 식품학적 또는 약학적인 용도로 제공하기 위한 것이다.Another object of the present invention is to identify the use of the extract and the active ingredient contained in the extract by the above-described method to provide a food or pharmaceutical use.
본 발명자는 상술한 목적을 달성하기 위한 결명자 분말을 여러 가지 추출용매로 수회실험한 결과 30~100%의 에탄올 수용액으로 추출하는 방법이 활성성분인 노르 루브로푸사린이 가장 많이 함유함을 알게 되었으며, 이 경우 노르-루브로푸사린이 0.005% 이상 함유하는 결명자 추출물을 얻을 수 있었다.As a result of several experiments with a variety of extraction solvents, the present inventors have found that the method of extracting 30% to 100% of an ethanol aqueous solution contains the most active ingredient, nor lubrofusarin. In this case, it was possible to obtain the extract of the deficiency containing no more than 0.005% of nor- lubrofusarin.
또한, 생체외 실험을 통하여 이들 추출물이 항산화 활성, 프리라디칼소거작용 및 항돌연변이 활성이 우수함을 알게 되었다. 특히, 체내에서 생성되는 활성산소 및 프리라디칼들은 눈과 같은 감각기관의 각종 조절근육을 약하게 만들고 눈으로 가는 동맥들도 경화시켜 망막에 공급되는 혈류량을 감소시키는 한편, 수정체의 투명도도 감소시킨다. 또한 활성산소 및 프리라디칼들은 체장의 β세포에 상해를 주어 당뇨병을 유발시키고 2차적으로 백내장 등의 안과적 질환을 야기시킨다. 또한, 자외선이나 각종 돌연변이원성물질들도 체내에서 돌연변이를 일으켜 백내장 등을 일으킬 수 있다. 따라서, 본 발명의 결명자 추출물의 항산화 활성, 프리라디칼 소거작용 및 항돌연변이 활성에 의하여 눈의 노화방지 및 안질환 예방제로서의 용도를 제공한다.In addition, through in vitro experiments, it was found that these extracts were excellent in antioxidant activity, free radical scavenging activity and antimutagenic activity. In particular, free radicals and free radicals produced in the body weaken the various regulating muscles of sensory organs such as the eye and harden the arteries to the eye to reduce blood flow to the retina, while also reducing the transparency of the lens. In addition, free radicals and free radicals injure β cells in the body, leading to diabetes, and secondly to ophthalmic diseases such as cataracts. In addition, ultraviolet rays and various mutagenic substances can also cause cataracts by mutating in the body. Therefore, the antioxidant extract, free radical scavenging activity and antimutagenic activity of the extract of the present invention provides the use of the eye as an anti-aging and eye disease prevention agent.
이하 본 발명을 실시예에 의하여 상세히 설명하겠지만 본 발명이 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, but the present invention is not limited to these Examples.
[실시예1]Example 1
·노르-루브로푸사린의 분리 및 정량법· Isolation and Assay of Nor-Lupurofusarin
결명자를 분말화한 후 70% 메탄올로 수육상에서 환류냉각 부착하여 가열하면서 3일간 추출하고 여과 후 여액을 감압건조하였다. 건조된 엑기스 50g를 소량의 메탄올에 녹인 후 용매로서 에틸아세테이트와 메탄올을 사용하여 반복하여 실리카겔 크로마토그래피하여 순수한 노르-루브로푸사린 약 50mg 얻었다. 이 물질의 구조는 기 발표된 데이터와 비교하여 동정하였으며 구조는 그림 1과 같다.After clarification of the deflector, the mixture was refluxed with a 70% methanol and reflux-cooled for 3 days while heating. The filtrate was dried under reduced pressure after filtration. 50 g of the dried extract was dissolved in a small amount of methanol, and then repeatedly purified by silica gel chromatography using ethyl acetate and methanol as a solvent to obtain about 50 mg of pure nor- lubrofusarin. The structure of this material was identified by comparison with published data and the structure is shown in Figure 1.
노르-루브로푸사린의 정량법은 결명자를 분말로 한 후 70% 에탄올 용액으로 3일간 추출하고 이를 여과하고 감압농축한다. 검체 100mg을 메탄올 50ml에 녹이고 이를 여과하여 HPLC용 검액으로 한다. 이때 칼럼은 ODS(Shimazu제), 이동상은 Methanol : Water : Acetic acid = 40 : 60 : 0.5, 검출기는 UV 254nm, 유량은 0.8/ml으로 실시하였다. 이때 노르-루브로푸사린은 약 30분의 유지시간을 나타내었다.In the quantitative determination of nor-brobrofusarin, the extractor was powdered, extracted with 70% ethanol solution for 3 days, filtered and concentrated under reduced pressure. Dissolve 100 mg of the sample in 50 ml of methanol, and filter it to obtain a sample solution for HPLC. At this time, the column was ODS (manufactured by Shimazu), the mobile phase was Methanol: Water: Acetic acid = 40: 60: 0.5, the detector was UV 254 nm, and the flow rate was 0.8 / ml. In this case, nor-brobrofusarin showed a holding time of about 30 minutes.
·결명자 추출물의 추출방법Extraction method of Clarifier extract
결명자의 추출에 미치는 인자들의 영향을 알기 위하여 결명자 분말(60g)을 검체로 하여 에탄올 수용액 600ml로 에탄올의 농도를 달리하면서 추출하였다. 이때 에탄올 0%(수용액 100%)일 때는 1일 동안 끓였으며 30%, 70%, 100%일 때는 20℃에서 3일간 추출하였다. 추출액을 여과하고 감압농축하여 결명자 추출물을 얻었다.In order to know the effect of the factors on the extraction of the deficiency extracter powder (60g) as a sample was extracted with varying concentration of ethanol to 600ml ethanol aqueous solution. At this time, when ethanol 0% (aqueous solution 100%) was boiled for 1 day, 30%, 70%, 100% when extracted for 3 days at 20 ℃. The extract was filtered and concentrated under reduced pressure to obtain the extract.
이들 결명자 추출물의 최종수율 및 이들 추출물에 함유된 노르-루브로푸사린 함량을 다음표 1에 나타내었다.The final yields of these extracts and the content of nor- lubrofusarin contained in these extracts are shown in Table 1 below.
상기표 1에서 알 수 있듯이 에탄올 농도가 높아질수록 결명자 추출물의 최종수율은 낮아졌지만, 결명자 추출물 중 노르-루브로푸사린은 수용액 100%로 추출하였을 때는 거의 검출되지 않았으나 70% 에탄올 및 100%에탄올에서 함량이 높아졌다.As can be seen in Table 1, the higher the ethanol concentration, the lower the final yield of the extract of C. oleracea, but no-rubrofusarin in the C. extract was hardly detected when extracted with 100% aqueous solution, but in 70% ethanol and 100% ethanol. The content was high.
[실시예2]Example 2
·항산화작용.Antioxidant activity.
결명자로부터 추출한 70% 에탄올 추출물 및 노르-루브로푸사린의 항산화 작용의 측정은 펜톤반응(Fenton reaction)에 의한 지질 과산화반응계(lipid peroxid ation system)을 이용한 TBA assay로 측정하였다. 즉, 에틸리놀레이트 10ul, 0.2% SDS, 염화제일철 10umol, 과산화수소 2umol을 함유하는 25mM 트리즈마(Trizma) HCl/0.75mM KCl 완충액 5ml에 검체들의 에탄올 추출물을 가한 후 55도에서 16시간 배양한 후 4% BHT 50ul를 가한 후 반응을 정지시킨다. 다음 이 용액 0.3ml를 시험관에 넣고 0.05N HCl 3.1ml, 0.67% TBA 용액을 가하고 30분간 끓인다. 다음 반응액을 냉각시킨 후 85% 부탄올 4.0ml을 가하고 원심분리 후 부탄올층의 흡광도를 535nm에서 측정하여 항산화효과(%)를 구한다. 이 항산화효과의 측정결과는 다음 표2와 같다.Determination of antioxidant activity of 70% ethanol extract and nor- lubrofusarin extracted from the defector was measured by TBA assay using a lipid peroxidation system by the Fenton reaction. In other words, 5 ml of 25 mM Trizma HCl / 0.75 mM KCl buffer containing 10ul of ethyl linoleate, 0.2% SDS, ferrous chloride, and 2umol of hydrogen peroxide were added to the ethanol extract of the samples, followed by incubation for 16 hours at 55 ° C. The reaction is stopped after adding 50ul of% BHT. 0.3 ml of this solution was added to a test tube, and 0.05 ml of HCl 3.1 ml and 0.67% TBA solution were added and boiled for 30 minutes. Next, after cooling the reaction solution, 4.0 ml of 85% butanol was added, and after centrifugation, the absorbance of the butanol layer was measured at 535 nm to obtain an antioxidant effect (%). The measurement results of this antioxidant effect are shown in Table 2 below.
표2에서 볼 수 있듯이 결명자 추출물은 추출용매에 에탄올 함량이 높을수록 1mg/ml과 0.01mg/ml에서의 활성이 크게 나타났으며 노르-루브로푸사린은 10 M - 10 M 사이에서 용량의존적으로 항산화활성을 나타내었다.As can be seen in Table 2, the extract of C. vulgaris showed higher activity at 1mg / ml and 0.01mg / ml as the ethanol content was higher in the extraction solvent. M-10 The dose-dependent antioxidant activity was shown between M.
·프리라디칼소거작용Free radical scavenging action
결명자 70% 에탄올추출물 및 노르-루브로푸사린의 프리라디칼소거작용의 측정은 60uM 1,1-디펜닐-2-피크릴 히드라질(1,1-diphenyl-2-picrylhydrazyl; DPPH) 에탄올용액 2ml에 검체들의 DMSO용액 2ml를 가해 30분간 상온에서 반응시킨 후 520nm에서 흡광도를 측정하여 프리라디칼소거작용(%)를 구한다. 이 측정결과는 다음표 3과 같다.Determination of free radical scavenging activity of 70% ethanol extract and nolu-brobrofusarin at 60 μM 1,1-diphenylyl-2-picryl hydrazyl (1,1-diphenyl-2-picrylhydrazyl; DPPH) ethanol solution 2 ml 2 ml of DMSO solution was added to the sample, reacted at room temperature for 30 minutes, and the absorbance was measured at 520 nm to determine the free radical scavenging effect (%). The measurement results are shown in Table 3 below.
표3에서 볼 수 있듯이 결명자 추출물은 30%에탄올 추출물보다 70%에탄올추출물이 0.01mg/ml 및 1mg/ml에서 활성이 크게 나타났으며, 노르-루브로푸사린은 10 M -10 M 사이에서 용량의존적으로 프리라디칼소거작용을 나타내었다.As can be seen in Table 3, the extract of C. vulgaris showed more activity at 0.01 mg / ml and 1 mg / ml than 70% ethanol extract, and no-rubrofusarin 10 M -10 A dose-dependent free radical scavenging action was shown between M.
·항돌연변이 작용Antimutagenic activity
결명자 70% 에탄올추출물 및 노르-루브로푸사린의 항돌연변이작용을 다음과 같이 측정하였다.Antimutagenic activity of 70% ethanol extract and no-robrofusarin was determined as follows.
즉, 마우스를 말초혈액을 이용한 소핵생성억제효과를 실시한다. 이때 사용하는 양성대조물질로는 마이토마이신 씨(mitomycin C, MMC) 1mg/kg를 복강주사하고 48시간 후에 꼬리에서 말초혈액을 채취하여 마이토마이신씨와 동시투여된 결명자 추출물 및 노르-루브로푸사린의 경구투여용량에 따른 소핵생성억제효과(%)를 관찰한다. 이 측정결과는 다음표 4와 같다.That is, the mouse performs the micronucleus suppression effect using peripheral blood. At this time, the positive control material used was intraperitoneal injection of 1 mg / kg of mitomycin C (MMC), and peripheral blood was collected from the tail after 48 hours. The effect of suppressing micronucleation (%) according to the oral dose of fusarin was observed. The measurement results are shown in Table 4 below.
표 4에서 볼 수 있듯이 결명자 추출물은 1mg/kg 및 10mg/kg에서 활성이 나타났으며 노르-루브로푸사린은 0.01mg/kg, 0.1mg/kg에서 마이토마이신 씨(MMC)에 대한 소핵생성을 억제시켜 항돌연변이활성을 나타내었다.As can be seen in Table 4, the extract of L. oleracea showed activity at 1 mg / kg and 10 mg / kg, and no-rubrofusarin at 0.01 mg / kg and 0.1 mg / kg for micronucleation for mitomycin seed (MMC). Inhibition showed antimutagenic activity.
상기 결과에 나타나듯이 이 조성물은 시험관내에서 0.01-1 mg/ml에서 항산화작용과 프리라디칼소거 작용이 나타났으며 마우스(ICR, 6-8주령)에서는 일회경구투여량 1-10mg/kg에서 유효한 항돌연변이 효과가 나타났다.As shown in the above results, the composition showed antioxidant and free radical scavenging effects at 0.01-1 mg / ml in vitro and effective at a single oral dose of 1-10 mg / kg in mice (ICR, 6-8 weeks of age). Antimutagenic effects were shown.
[실시예 3]Example 3
[제제의 제조][Production of Preparation]
정제는 1정당 이 조성물 20-200mg과 락토스 150mg, 스타치 25mg, 마그네슘 스테아레이트 10mg을 혼합하여 타정하여 제조한다. 액제는 10ml당 이 조성물 20-200mg과 이성화당 2g, 백당 2g, 배즙 10g을 가하고 이를 정제수에 녹여 액제로 제조한다.Tablets are prepared by mixing 20-200 mg of this composition with 150 mg of lactose, 25 mg of starch and 10 mg of magnesium stearate per tablet. The solution is prepared as a solution by adding 20-200 mg of the composition, 2 g of isomerized sugar, 2 g of white sugar, and 10 g of pear juice per 10 ml and dissolving it in purified water.
[실시예 4]Example 4
[급성독성][Acute Toxicity]
참고로 이 조성물의 급성독성 시험은 마우스(ICR, 6-8주령)에 적용하였으며 이 결과 웅성의 마우스에서 5g/kg(경구투여)에서 죽은 개체가 발생하지 않았으며 중요장기의 변화나 체중감소 등의 이상도 나타나지 않았다. 자성의 마우스에서도 웅성에서와 마찬가지의 결과를 얻었으며 따라서 이 조성물은 안전하다고 판단되었다.For reference, the acute toxicity test of this composition was applied to mice (ICR, 6-8 weeks of age). As a result, no males died at 5 g / kg (oral administration) in male mice. Did not appear abnormal. The same results were obtained in the male mice as in the male, and thus the composition was considered safe.
상기 실시예에 나타난 바와 같이 본 발명의 방법에 의한 결명자로부터 활성성분의 추출은 노르-루브로푸사린을 고수율로 추출할 수 있으며 특히, 이들 추출물들은 항산화, 프리라디칼소거작용 및 항돌연변이작용활성을 나타내는 것으로 이들 활성이 뒷받침하는 눈의 노화방지 및 안질환예방제로서 유용한 것이다.As shown in the above examples, the extraction of the active ingredient from the cultivars according to the method of the present invention can extract nor- lubrofusarin in high yield, in particular, these extracts have antioxidant, free radical scavenging and antimutagenic activity. It is useful as an anti-aging and eye disease preventive agent of the eye supported by these activities.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950036567A KR0168721B1 (en) | 1995-10-23 | 1995-10-23 | Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950036567A KR0168721B1 (en) | 1995-10-23 | 1995-10-23 | Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970020112A KR970020112A (en) | 1997-05-28 |
KR0168721B1 true KR0168721B1 (en) | 1999-01-15 |
Family
ID=19430914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950036567A KR0168721B1 (en) | 1995-10-23 | 1995-10-23 | Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR0168721B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100406158B1 (en) * | 2001-03-06 | 2003-11-15 | 조진원 | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process |
KR100444124B1 (en) * | 2001-08-16 | 2004-08-09 | 이회선 | Composition for inhibiting mycotoxin production |
WO2007061243A1 (en) * | 2005-11-24 | 2007-05-31 | Inno Pharm Co., Ltd. | Composition comprising the extract of cassiae semen for treating or preventing cognitive dysfunction |
KR100765436B1 (en) * | 2005-10-25 | 2007-10-09 | 경북대학교 산학협력단 | Methods for increasing aurantio-obtusin content in Cassiae Semen, and the method for extraction of aurantio-obtusin having increased contents |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100478136B1 (en) * | 2001-10-24 | 2005-03-21 | 주식회사 내츄로바이오텍 | Extracts derived from plant that have anti-oxidation activity |
-
1995
- 1995-10-23 KR KR1019950036567A patent/KR0168721B1/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100406158B1 (en) * | 2001-03-06 | 2003-11-15 | 조진원 | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process |
KR100444124B1 (en) * | 2001-08-16 | 2004-08-09 | 이회선 | Composition for inhibiting mycotoxin production |
KR100765436B1 (en) * | 2005-10-25 | 2007-10-09 | 경북대학교 산학협력단 | Methods for increasing aurantio-obtusin content in Cassiae Semen, and the method for extraction of aurantio-obtusin having increased contents |
WO2007061243A1 (en) * | 2005-11-24 | 2007-05-31 | Inno Pharm Co., Ltd. | Composition comprising the extract of cassiae semen for treating or preventing cognitive dysfunction |
Also Published As
Publication number | Publication date |
---|---|
KR970020112A (en) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4873824B2 (en) | Carbohydrate absorption inhibitor and method for producing the same | |
WO2008083513A1 (en) | Black soybean hull extract and process for preparation and use thereof | |
AU2011342118B2 (en) | Oxidation reaction product of hop extract, process for production thereof, and use thereof | |
JP2514860B2 (en) | Hop extract used for elimination of active oxygen and its utilization | |
JPH092917A (en) | Polyphenol preparation obtained from hop and its production | |
JPWO2011108059A1 (en) | Xanthine oxidase inhibitor | |
KR0168721B1 (en) | Process for preparing the extracts of cassiae semen, and pharmaceutical compositions containing them useful for antioxidant, free radical scavenger, antimutagent and opthalimic disease preventing agent | |
US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
EP1602704A1 (en) | Antioxidant, skin preparation for external use, cosmetic and food | |
US20100197643A1 (en) | Phytochemical-rich oils and methods related thereto | |
WO2011112002A2 (en) | Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient | |
KR20030025200A (en) | Substances extracted from corn which can inhibit the activities of amylase, pharmaceutical compositions and food additives containing the same extracts for treatment or prevention of obesity and diabetes mellitus, and processes for their preparation | |
JP2008174457A (en) | 2-(2-METHYLPROPANOYL)PHLOROGLUCINOL-1,5-DI-O-beta-D-GLUCOPYRANOSIDE HAVING ANTIOXIDANT ACTION | |
KR100839185B1 (en) | Composition comprising plantamajoside for treating or preventing diabete and diabetic complication | |
JP4532257B2 (en) | A novel polyphenol glycoside derived from acerola | |
Carole et al. | Phytochemical profile and free radical scavenging activities of methanol extract of green pea | |
KR20140137640A (en) | Complex extract of Quercus variabilis fractions and composition for treating or preventing diabetes comprising the same | |
JP2006056793A (en) | Method for producing polyphenol-containing product, polyphenol-containing product, alpha amylase inhibitor, antioxidant, and edible composition | |
JP2776927B2 (en) | Brain function improver | |
KR20200117957A (en) | A composition for preventing or treating atopic dermatitis comprising the extract of corn silk | |
JP4414711B2 (en) | Active oxygen scavenger and method for producing the same | |
KR102668013B1 (en) | Anti-inflammatory Composition Using (1R,4S,6S)-1,6-dihydroxy-2-menthene | |
JPWO2005056031A1 (en) | Lipase inhibitor | |
WO2024096220A1 (en) | Immune boosting composition comprising seaweed extracts | |
KR102281794B1 (en) | Composition for protecting hepatic damage on heavy metal comprising extracts from Dendropanax morbifera |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111004 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20120928 Year of fee payment: 15 |
|
LAPS | Lapse due to unpaid annual fee |